{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:52:50Z","timestamp":1777953170129,"version":"3.51.4"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, the results of randomized controlled trials on overall survival (OS). The IPDfromKM method was employed for reconstruct individual patient data (IPD) from the graphs of Kaplan\u2013Meier curves. Cox statistics was run to estimate hazard ratios (HRs). Results: After a literature search on Medline (via PubMed) and Scopus databases, six randomized controlled trials were identified in which five new treatments (nivolumab plus ipilimumab, bevacizumab plus pemetrexed plus cisplatin, chemotherapy plus pembrolizumab, ONCOS-102 plus pemetrexed plus cisplatin\/carboplatin and cediranib plus pemetrexed+cisplatin with maintenance with cediranib) were evaluated. In five trials, pemetrexed plus cisplatin was the standard of care given to the control arms. Nivolumab plus ipilimumab, bevacizumab plus pemetrexed plus cisplatin and chemotherapy plus pembrolizumab showed a significantly better OS compared with controls. ONCOS-102 plus pemetrexed plus cisplatin\/carboplatin did not significantly improve OS. In contrast, OS worsened with cisplatin alone and with cediranib plus pemetrexed+cisplatin with maintenance with cediranib. Discussion: Our analysis indicates that, in patients with unresectable pleural mesothelioma, three of the five novel treatments provided a significant survival benefit compared with the standard of care. Further research is needed to confirm the OS benefit found in our analysis with some treatments, whereas cisplatin alone and cediranib plus pemetrexed+cisplatin with maintenance with cediranib do not seem to deserve further research.<\/jats:p>","DOI":"10.3390\/cancers17030503","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:35:07Z","timestamp":1738575307000},"page":"503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5829-107X","authenticated-orcid":false,"given":"Andrea","family":"Messori","sequence":"first","affiliation":[{"name":"HTA Unit, Regione Toscana, 50136 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Trippoli","sequence":"additional","affiliation":[{"name":"HTA Unit, Regione Toscana, 50136 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-3065","authenticated-orcid":false,"given":"Eugenia","family":"Piragine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, 56126 Pisa, Italy"},{"name":"School of Specialization in Hospital Pharmacy, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0278-9446","authenticated-orcid":false,"given":"Sara","family":"Veneziano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Calderone","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/jtd-20-2761","article-title":"Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature","volume":"13","author":"Schumann","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kindler, H.L., Ismaila, N., Bazhenova, L., Chu, Q., Churpek, J.E., Dagogo-Jack, I., Bryan, D.S., Drazer, M.W., Forde, P., and Husain, A.N. (J. Clin. Oncol., 2025). Treatment of Pleural Mesothelioma: ASCO Guideline Update, J. Clin. Oncol., ahead of print.","DOI":"10.1200\/JCO-24-02425"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.12688\/f1000research.15512.2","article-title":"Factors influencing malignant mesothelioma survival: A retrospective review of the National Mesothelioma Virtual Bank cohort","volume":"7","author":"Amin","year":"2018","journal-title":"F1000Research"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4997\/JRCPE.2015.207","article-title":"Survival from malignant mesothelioma: Where are we now?","volume":"45","author":"Marshall","year":"2015","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41379-019-0352-3","article-title":"Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: Best current evidence from the literature and the International Mesothelioma Panel","volume":"33","author":"Marchevsky","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.21037\/jtd.2017.10.16","article-title":"Surgery for malignant pleural mesothelioma: An international guidelines review","volume":"10","author":"Ricciardi","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pezzicoli, G., Rizzo, M., Perrone, M., Minei, S., Mutti, L., and Porta, C. (2021). A Glimpse in the Future of Malignant Mesothelioma Treatment. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.809337"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14737140.2017.1340157","article-title":"First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma","volume":"17","author":"Fujimoto","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate-743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: A phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e007552","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: A randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J. Immunother. Cancer."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemotherapy-Na\u00efve Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.22.02542","article-title":"Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma","volume":"41","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/1120009X.2022.2061183","article-title":"Current treatments for inoperable mesothelioma: Indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials","volume":"35","author":"Messori","year":"2023","journal-title":"J. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Liu, N., Zhou, Y., and Lee, J.J. (2021). IPDfromKM: Reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01308-8"},{"key":"ref_21","first-page":"e19422","article-title":"Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve","volume":"13","author":"Messori","year":"2021","journal-title":"Cureus"},{"key":"ref_22","unstructured":"Messori, A. (2024). Reconstruction of individual-patient data from the analysis of Kaplan-Meier curves: This method is widely used in oncology and cardiology\u2014List of 53 studies in oncology and 61 in cardiology (preprint). Open Sci. Framew."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Piragine, E., Veneziano, S., Trippoli, S., Messori, A., and Calderone, V. (2024). Efficacy and Safety of Cardioband in Patients with Tricuspid Regurgitation: Systematic Review and Meta-Analysis of Single-Arm Trials and Observational Studies. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216393"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13643-019-1032-6","article-title":"Individual participant data (IPD)-level meta-analysis of randomised controlled trials among dark-skinned populations to estimate the dietary requirement for vitamin D","volume":"8","author":"Cashman","year":"2019","journal-title":"Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wach, J., Vychopen, M., G\u00fcresir, A., Guranda, A., Nestler, U., and G\u00fcresir, E. (2024). A Long-Term Comparative Analysis of Endovascular Coiling and Clipping for Ruptured Cerebral Aneurysms: An Individual Patient-Level Meta-Analysis Assessing Rerupture Rates. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061778"},{"key":"ref_26","first-page":"616","article-title":"Totally Endoscopic Coronary Artery Bypass Graft: Systematic Review and Meta-Analysis of Reconstructed Patient-Level Data","volume":"19","author":"Zoupas","year":"2024","journal-title":"Innovations"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23814683221077643","DOI":"10.1177\/23814683221077643","article-title":"A Method for Reconstructing Individual Patient Data from Kaplan-Meier Survival Curves That Incorporate Marked Censoring Times","volume":"7","author":"Rogula","year":"2022","journal-title":"MDM Policy Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_29","unstructured":"R Core Team (2023). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S1470-2045(21)00702-6","article-title":"CONFIRM trial: What is the real efficacy of second-line immunotherapy in mesothelioma?","volume":"23","author":"Correale","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/cam4.5067","article-title":"Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data","volume":"12","author":"Ossato","year":"2023","journal-title":"Cancer Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:26:06Z","timestamp":1760027166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030503"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030503","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}